FDA Inspection
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc. – FDA Inspection, Nov 7, 2024
Record Details
This FDA Inspection record concerns Alexion Pharmaceuticals, Inc., with an inspection on November 7, 2024, issued by the New England District Office, covering human drugs.
View Company Profile
ID · 5b301914-bf94-449d-9b3e-8f8c86990b4e
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1254018
- FDA center
- Human Drugs
- Project area
- Postmarketing Surveillance and Epidemiology: Human Drugs
FDA Citations
4- 21 CFR 314.80(b)Failure to develop written procedures
- 21 CFR 314.80(c)(2)(ii)(B)Late submission of an ICSR
- 21 CFR 314.80(c)(1)(i)Late submission of 15-day report
- 21 CFR 314.80(b)Failure to review ADE information
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Alexion Pharmaceuticals, Inc.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| July 28, 2026 | Not classified | New England District Office | |
| July 1, 2026 | Not classified | New England District Office | |
| March 7, 2025 | VAI | New England District Office | Postmarketing Surveillance and Epidemiology: Human Drugs |
| September 14, 2023 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| June 30, 2023 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Alexion Pharmaceuticals, Inc.
- FDA Inspection 1330676 - 2026-07-28
- FDA Inspection 1326206 - 2026-07-01
- FDA Inspection 1262947 - 2025-03-07
- FDA Inspection 1219061 - 2023-09-14
- FDA Inspection 1218199 - 2023-06-30
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.